This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Pulmonary Diseases  • Asthma  • Immunology  • Allergy  • Alert me on articles by topic  Social Bookmarking   What's this?

Nahed O. ElHassan, MD, MPH; Melony E. S. Sorbero, PhD, MS, MPH; Caroline B. Hall, MD; Timothy P. Stevens, MD, MPH; Andrew W. Dick, PhD

Arch Pediatr Adolesc Med. 2006;160:1070-1076.

Objectives  To evaluate the cost-effectiveness of palivizumab as respiratory syncytial virus prophylaxis in premature infants without chronic lung disease and to evaluate the impact on cost-effectiveness of a potential reduction in risk of asthma following respiratory syncytial virus infection among infants receiving palivizumab.

Design  Two decision analytic models were designed, one with and the other without accounting for increased risk of asthma following respiratory syncytial virus infection.

Setting  A hypothetical community or university hospital.

Participants  Hypothetical cohorts of infants without chronic lung disease born at 26 to 32 weeks' gestation.

Interventions  Palivizumab prophylaxis vs no prophylaxis.

Main Outcome Measures  Expected costs and incremental cost-effectiveness ratio expressed as cost per quality-adjusted life-year.

Results  The expected costs were higher for palivizumab prophylaxis as compared with no prophylaxis. The incremental cost-effectiveness ratios were high for all gestations and are not considered cost-effective by today's standards (<$200 000 per quality-adjusted life-year). Both models were sensitive to variation in the cost of palivizumab. The model that included asthma was sensitive to variation in quality of life for children with asthma. In instances where asthma was considered severe with profound worsening in quality of life compared with life without asthma, some infants had an incremental cost per quality-adjusted life-year that was less than $200 000.

Conclusions  Our model supports implementing more restrictive guidelines for palivizumab prophylaxis. Palivizumab was cost-effective for some infants in an analysis that accounted for increased risk of severe asthma following respiratory syncytial virus infection.

Author Affiliations: Division of Neonatology, Department of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock (Dr ElHassan); RAND Corp, Pittsburgh, Pa (Drs Sorbero and Dick); and Divisions of Infectious Disease (Dr Hall) and Neonatology (Dr Stevens), Department of Pediatrics, Strong Children's Research Center, Rochester, NY.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Immunoprophylaxis in the Reduction of Disease Attributable to Respiratory Syncytial Virus
Meissner et al.
Pediatrics 2009;124:1676-1679.
FULL TEXT  

Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections
Committee on Infectious Diseases
Pediatrics 2009;124:1694-1701.
ABSTRACT | FULL TEXT  

Costs Associated With Ventricular Assist Device Use in Children
Mahle et al.
Ann. Thorac. Surg. 2008;86:1592-1597.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis With Palivizumab
Mahadevia and Malinoski
Arch Pediatr Adolesc Med 2007;161:519-520.
FULL TEXT  

Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis With Palivizumab--Reply
Sorbero et al.
Arch Pediatr Adolesc Med 2007;161:520-520.
FULL TEXT